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Nitric oxide (NO) is a typical gaseous messenger involved in a wide range of biological
processes. In our classical knowledge, effects of NO are largely achieved by activation
of soluble guanylyl cyclase to form cyclic guanosine-3′, 5′-monophosphate. However,
emerging evidences have suggested another signaling mechanism mediated by NO:
“S-nitrosylation” of target proteins. S-nitrosylation is a covalent addition of an NO group
to a cysteine thiol/sulfhydryl (RSH), and categorized into non-enzymatic post-translational
modification (PTM) of proteins, contrasted to enzymatic PTM of proteins, such as phos-
phorylation mediated by various protein kinases. Very recently, we found novel intracellu-
lar calcium (Ca2+) mobilizing mechanism, NO-induced Ca2+ release (NICR) in cerebellar
Purkinje cells. NICR is mediated by type 1 ryanodine receptor (RyR1), a Ca2+ release chan-
nel expressed in endoplasmic-reticular membrane. Furthermore, NICR is indicated to be
dependent on S-nitrosylation of RyR1, and involved in synaptic plasticity in the cerebel-
lum. In this review, molecular mechanisms and functional significance of NICR, as well as
non-enzymatic PTM of proteins by gaseous signals, are described.
Keywords: gaseous messenger, post-translational modification, nitric oxide, ryanodine receptor, S-nitrosylation,
calcium release, synaptic plasticity, Purkinje cell
INTRODUCTION
Primary structure of proteins obtained from genome analysis is
not sufficient to explain their various biological functions: while
it is estimated that the human genome, for example, comprises
∼27,000 genes, the total number of proteins in the human pro-
teome is estimated at over one million. In addition to changes at the
transcriptional and mRNA levels, it is now increasingly recognized
that “post-translational modification (PTM) of proteins” provide
important roles in a wide range of signaling pathways, including
intercellular signaling pathways such as endocrine systems as well
as intracellular pathways. PTMs are covalent processing events
that change the properties of a protein by proteolytic cleavage
or by addition of a modifying group to one or more amino acids.
PTMs of proteins are indicated to be involved in various biological
events through changes in protein activity, their cellular locations
and dynamic interactions with other proteins (1, 2).
More than 300 different types of PTMs are currently known,
and new ones are regularly discovered (3). In general, PTMs are
categorized into two groups: enzymatic modification and non-
enzymatic modification. Enzymatic PTM, including phosphory-
lation, acetylation, glycosylation, and lipidation, are demonstrated
to be involved in a wide range of physiological and pathophysio-
logical events in eukaryotic cellular systems. On the other hand,
accumulation of products derived from non-enzymatic PTM is
seen in various tissues of metabolic and age-related diseases
such as Alzheimer’s disease, Parkinson’s disease, cataractogenesis,
atherosclerosis, diabetic secondary complications, etc. (4–7). Con-
sequently, it is thought that these accumulations are possibly
causative to age-related pathology, and non-enzymatically mod-
ified proteins are considered to be useful biomarkers for these
diseases (8, 9).
However, recent studies indicate that non-enzymatic PTM of
proteins is also associated with physiological events. For example,
S-nitrosylation by nitric oxide (NO) is now well established as a
major source of NO bioactivity (10–12), and proteins shown to
be modified in situ by S-nitrosylation (SNO-proteins) participate
in a wide range of biological process including those involved
in cellular trafficking (13), muscle contractility (14), apopto-
sis (15, 16), and circulation (17). In addition to non-enzymatic
PTMs by reducing molecules, such as glycation by glucose, non-
enzymatic modification by gaseous messengers is now attracting
much attention.
POST-TRANSLATIONAL MODIFICATION BY GASEOUS
MESSENGERS
A gas is a state of matter different from either the liquid or solid
states. Gases possess the ability to diffuse readily in different mate-
rials and distribute uniformly within a defined space. Biological
gases are assumed to diffuse freely across biologic membranes (18).
Thus, gases do not bind to cell surface receptors, and do not require
the intermediation of conventional membrane receptors and sec-
ond messenger machinery such as G-proteins and adenylyl cyclase
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(19). Instead, the gases directly interact with targets, such as guany-
lyl cyclase (20). In addition to the reactions with metal centers of
metalloproteins (e.g., hemoglobin), significant proportion of the
direct action of gaseous messengers is mediated through non-
enzymatic PTM of proteins, such as S-nitrosylation by NO and
sulfhydration of hydrogen sulfide (H2S) (21–23).
Probably most prevalent is the “S-nitrosylation” by NO. NO is
produced enzymatically in cells expressing NO synthase (NOS)
(19). Addition of NO group to the thiol side chain of cysteine
residues within proteins and peptides is termed S-nitrosylation.
Furthermore, peroxynitrite, produced by the reaction of NO with
superoxide, is demonstrated to regulate cellular signaling (24).
Peroxynitrite reacts with several amino acids. Cysteine, methio-
nine, and tryptophan react directly, whereas tyrosine, phenylala-
nine, and histidine are modified through intermediary secondary
species (25). Therefore, emerging evidence have indicated that
non-enzymatic PTM of proteins by gaseous messengers is involved
in physiological and pathological events in various biological
systems (26).
FUNCTIONAL MODIFICATION OF RYANODINE RECEPTORS
BY S-NITROSYLATION
Skeletal and cardiac muscles mainly express neuronal NOS
(nNOS) and endothelial NOS (eNOS), respectively (27, 28), and
endogenously produced NO can promote two physiological func-
tions of these muscles. The first is to induce relaxation through
the cGMP signaling pathway (29, 30). The second is to mod-
ulate increases in contraction that are dependent on reactive
oxygen intermediates and independent on cGMP (27). Stoy-
anovsky et al. (31) thus examined effects of NO-related com-
pounds on Ca2+ release from sarcoplasmic reticulum (SR) isolated
from skeletal and cardiac muscles (31). The compounds, such
as S-nitrosocysteine (cysNO), S-nitroso-N -acetylpenicillamine
(SNAP), and S-nitrosylated glutathione (GSNO), induced Ca2+
release from the isolated SR vesicles. Correspondingly, applica-
tion of SNAP increased open probability of SR channels in lipid
bilayer (31). The effects of NO-related compounds on the activity
of Ca2+ release channels were observed in subsequent study: Xu
et al. (14) showed that GSNO and cysNO increased open proba-
bility of cardiac Ca2+ release channel in lipid bilayer (14). In this
study, the rise in open probability of cardiac Ca2+ release chan-
nel was accompanied with the increased amount of S-nitrosothiol
group per channel protein, the result suggesting the activation of
cardiac Ca2+ release channels by S-nitrosylation (14). However,
as is demonstrated later, NO or 1-hydroxy-2-oxo-3-(N -ethyl-2-
aminoethyl)-3-ethyl-1-triazene (NOC12) (an NO donor) do not
activate or S-nitrosylate RyR2 while GSNO induce activation and
S-nitrosylation of RyR2 (32). Thus, at that time, cardiac Ca2+
release channels, possibly RyR2, was suggested to be activated by
GSNO-induced S-nitrosylation of the channel (14).
Subsequently, NO-induced S-nitrosylation of skeletal Ca2+
release channel was demonstrated. In these studies, NO-sensitivity
of the channels had been studied extensively in ambient O2 tension
(pO2 ∼150 mmHg), whereas tissue pO2 is ∼10–20 mmHg and
even lower in exercising muscle (33, 34). Eu et al. (35) showed that
Ca2+ release channel in SR isolated from skeletal muscle, possibly
type 1 ryanodine receptor (RyR1), was activated and S-nitrosylated
by submicromolar concentration of NO (35). This modification
of the channel was induced restrictedly in the case that pO2 was at
tissue level (∼10 mmHg) but not at ambient level (∼150 mmHg).
However, when the concentration of NO was increased to micro-
molar ranges, the channels were activated by NO even in the
ambient O2 levels (35). Moreover, unlike the case in NO, activation
of the channels by NOC12 or GSNO was indicated to be insen-
sitive to pO2 levels: NOC12 and GSNO activated skeletal Ca2+
channels in SR at ambient O2 levels even when the concentration
of these compounds were low enough and the estimated levels of
NO produced from these compounds were submicromolar ranges
(36).
Eu et al. (35) also estimated that only one cysteine in RyR1 was
S-nitrosylated by submicromolar concentrations of NO at tissue
O2 level (35). Subsequently, the target of S-nitrosylation was iden-
tified as Cys3635: single-cite C3635A-mutaion in RyR1 abolished
NO-induced S-nitrosylation of the mutated channels expressed
in HEK 293 cells (37). In addition, the NO-induced rise in open
probability was abolished in the C3635A-mutant channels in lipid
bilayer (36). C3635 is intercalated within the hydrophobic calmod-
ulin (CaM)-binding domain of RyR1, and thereby S-nitrosylation
of C3635 is thought to reverse channel inhibition by CaM (38–
40). Furthermore, C3635 was indicated to be not required for the
activation of the channel by GSNO (36). Taken together, these
observations suggest that NO, NOC12, and GSNO activate the
redox-sensitive RyR1 channel by different mechanisms, and the
effect of O2 tension on S-nitrosylation by NO is best rationalized
by an allosteric mechanism (36).
It is also demonstrated that RyR2 is not activated by NO and
the response of RyR3 to NO is much smaller than that of RyR1 (32,
41). Because the important cysteine (i.e., C3635 of rabbit RyR1) is
conserved among all RyR subtypes, the three-dimensional struc-
ture around the critical cysteine residue may be important for the
subtype specificity of S-nitrosylation or channel gating. However,
this mechanism requires further clarification.
BIOLOGICAL FUNCTION OF RyR1
Type 1 ryanodine receptor is an intracellular calcium release chan-
nel involved in regulation of cytosolic calcium levels. The highest
levels of RyR1 expression are observed in skeletal muscle, and sig-
nificantly higher levels of RyR1 mRNA are seen in the esophagus
and testis, when compared to other tissues (42). In addition, lower
amount are found in the spleen, gut kidney, stomach, submaxil-
lary gland, thymus, adrenal gland, and ovary. In mammalian brain,
RyR1 mRNA is prominent in the cerebellar Purkinje cell (PC)
layer and dentate dyrus in the hippocampal region (43). It is well
known that RyR1 is essential for contraction of skeletal muscles.
However, the function of RyR1 has yet to be clarified in the other
tissues, because the mutant deficient in RyR1 gene shows postnatal
lethality (44). Furthermore, RyR1 is demonstrated to be physio-
logically regulated by protein–protein interaction to voltage-gated
calcium channels in skeletal muscle cells (45). Although RyR1 is
also expressed in the brain, as is described above, such tight Ca2+
channel-mediated regulation of intracellular Ca2+ release through
RyR1, as seen in skeletal muscle cells, is absent in central neurons
(46). Therefore, further study into the regulatory mechanisms and
functions of RyR1 in the brain is warranted.
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NO-INDUCED Ca2+ RELEASE INDUCED BY NEURONAL
ACTIVITY
As is described so far, the redox regulation of RyRs were exten-
sively studied using in vitro experimental systems, especially in
lipid bilayer and SR isolated from skeletal and cardiac muscles.
On the other hand, involvement of S-nitrosylation of RyR in Ca2+
release in living cells and physiological function of the channel
modulation by endogenous NO have yet to be demonstrated,
although increased open probability of RyR1 by S-nitrosylation
was suggested to enhance Ca2+ leakage from skeletal muscle Ca2+
stores (SR) under pathological conditions (47, 48).
Involvement of S-nitrosylation in neuronal function has been
suggested in the cerebellar cortex. PCs, the principal and solely
output neurons in the cerebellar cortex, receive two types of
excitatory (glutamatergic) inputs: climbing fiber, originate from
inferior olive, and parallel fiber (PF), axon of cerebellar gran-
ule cells (49). The PF-to-PC synapse (PF synapse) is extensively
studied, because many studies indicate that long-term depression
(LTD), a kind of synaptic plasticity, of PF synapse is a cellular basis
for the cerebellar-dependent learning such as eyeblink condition-
ing (49–51). In addition to LTD, long-term potentiation (LTP) is
observed in PF synapse (PF-LTP). When PF are repeatedly stimu-
lated, the current response of PF synapse is potentiated for 30 min,
at least. Three groups demonstrated that the PF-LTP is depen-
dent on NO signals (52–54). Furthermore, although the protocol
(the stimulus pattern) for the LTP induction are slightly differ-
ent between Lev-Ram et al. (53) and Namiki et al. (54), both
groups demonstrated that this NO-dependent LTP is insensitive
to 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a selec-
tive inhibitor of sGC activation by NO (53, 54). Thus, PF-LTP
is indicated to be dependent on signaling pathways mediated by
S-nitrosylation. Furthermore, in their preliminary experiments,
Kakizawa et al. observed that PF-LTP was dependent also on intra-
cellular Ca2+ signals. Taken together, PF-LTP was indicated to be
dependent on S-nitrosylation and Ca2+ signals, and these results
lead to our hypothesis: S-nitrosylation-mediated Ca2+ release is
induced by PF activity and involved in the induction of PF-LTP.
First, Kakizawa et al. (41) demonstrated that bath application
of 1-hydroxy-2-oxo-3-(N -methyl-3-aminopropyl)-3-methyl-1-
triazene (NOC7), an NO donor, induced Ca2+ elevation in cere-
bellar PC in acute slice preparation from young-adult (1- to
2-month-old) mice (41). Subsequently, this NO-induced Ca2+
elevation was revealed to be Ca2+ release mediated by RyR1: the
NO-induced Ca2+ increase was abolished by thapsigargin, cyclop-
iazonic acid (CPA) [inhibitors of sarco/endoplasmic-reticulum
Ca2+ ATPase (SERCA)], and dantrolene (a specific inhibitor for
RyR1), but insensitive to chelating the extracellular Ca2+ and
heparin (a specific inhibitor for IP3Rs) (Figure 1). Involvement
of RyR1 was further confirmed by impaired NO-induced Ca2+
elevation in PCs in RyR1-knockout mice (44). Moreover, RyR1
was indicated to be necessary and sufficient for NO-induced Ca2+
increase by the experiment using HEK 293 cells, expressing lit-
tle endogenous RyRs: NO-induced Ca2+ elevation was observed
only in the cells expressing exogenous RyR1, identified by Ca2+
response to caffeine, a well-known agonist of RyRs. Furthermore,
NO-induced Ca2+ increase was indicated to be insensitive to
ODQ, a sGC inhibitor. The result suggested that the Ca2+ increase
FIGURE 1 | A schematic diagram of signaling pathways for NO-induced
Ca2+ release. NO, produced at PF terminal, diffuse and induce Ca2+
increase in Purkinje cell. This NO-induced Ca2+ increase is sensitive to
NAME (broad NOS inhibitor), Asc (reducing reagent), DTL (RyR1
antagonist), and TG (SERCA inhibitor), but not affected by ODQ (sGC
inhibitor), heparin (IP3R antagonist), and uric acid (peroxynitrite scavenger).
Thus, the Ca2+ increase is revealed to be Ca2+ release mediated by
S-nitrosylation of RyR1 by endogenous NO.
is independent on sGC-mediated pathways, including activation
of RyRs by cyclic ADP ribose, whose formation is induced by
cGMP (55). Instead, the result indirectly suggested that NO-
induced Ca2+ increase is dependent on S-nitrosylation of proteins
(Figure 1). Correspondingly, biochemical analysis indicated that
NO-induced Ca2+ elevation was accompanied with the transient
increase in S-nitrosylation levels of endogenous RyR1 in cerebel-
lar slices. NO-induced increase in S-nitrosylation level was also
observed in exogenous RyR1 expressed in HEK cells. Thus, NO-
induced Ca2+ elevation was revealed to be Ca2+ release mediated
by RyR1 (Figure 1), and was named “NO-induced Ca2+ release
(NICR)” (41).
Subsequently, Kakizawa et al. (41) examined induction of NICR
by physiological patterns of neuronal activity. When the burst
stimulus (BS) inducing PF-LTP was applied to PF, Ca2+ levels in
PCs were transiently but clearly elevated. This BS-induced Ca2+
increase was indicated to be Ca2+ release mediated by RyR1,
because the Ca2+ increase was abolished by bath application
of thapsigargin, CPA, and dantrolene. Furthermore, BS-induced
Ca2+ elevation was inhibited by NG-nitro-l-arginine methyl ester
(l-NAME), a broad antagonist of NOSs, and abolished also in
nNOS-knockout mice (56). Taken together, BS-induced Ca2+ ele-
vation was revealed to be dependent on both NO signals and Ca2+
release through RyR1 (Figure 1). Thus, BS-induced Ca2+ increase
is indicated to be NICR, and NICR is demonstrated to be induced
by physiological patterns of neuronal activity.
Neuronal activity in conjunction with certain forms of synaptic
plasticity may be associated with superoxide generation, and NO
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generation leads to peroxynitrite formation when superoxide is
simultaneously generated (57, 58). Because peroxynitrite is known
to regulate cell signaling via molecular modifications, including
protein nitration (57, 58), it seems possible that NICR is affected
by peroxynitrite produced from endogenous NO in the presence
of superoxide. Therefore, Kakizawa et al. (59) examined the poten-
tial role of peroxynitrite in the BS-induced Ca2+ release and LTP
(59). Bath application of the peroxynitrite scavenger, uric acid, and
the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-
sulfonatophenyl)porphyrinato iron(III) (FeTPPS), had no effect
on BS-induced Ca2+ increase), although the concentration of uric
acid (100µM) and FeTPPS (10µM) were thought to be high
enough. In accordance with the insensitivity of NICR to these
reagents, neither uric acid nor FeTPPs impaired the induction of
PF-LTP induced by BS. These results do not support the involve-
ment of peroxynitrite in NICR and PF-LTP induction, and NICR
is indicated to by induced directly by endogenous NO (Figure 1).
PHYSIOLOGICAL FUNCTION OF NICR
Because the BS, which induces NICR, has been already indi-
cated to induce PF-LTP (54), it is strongly suggested that NICR
is involved in the induction of PF-LTP. Actually, all manipula-
tions that inhibit NICR (application of l-NAME, thapsigargin,
and dantrolene; see also Figure 1) abolished PF-LTP in PCs. In
addition, neither PF-LTP nor NICR was induced in the cerebel-
lum of nNOS-knockout mice. Furthermore, both PF-LTP and
NICR were inhibited by intracellular application of ascorbic acid
from patch pipette (Figure 1). Because ascorbic acid is a reduc-
ing agent, the results also support the idea that S-nitrosylation
is required for the induction of NICR as well as PF-LTP. On the
other hand, bath application of uric acid, a scavenger of peroxyni-
trite (ONOO−, produced by reaction of NO with superoxide),
or pipette application of heparin inhibited neither NICR nor
PF-LTP. Taken together, NICR is revealed to be induced by phys-
iological activity of PF and essential for the induction of PF-LTP,
and these observations strongly indicate that Ca2+ release medi-
ated by S-nitrosylation of RyR1 is induced in living cells and has
physiological function(s) (41) (Figure 1).
PERSPECTIVES: POSSIBLE INDUCTION AND PHYSIOLOGICAL
FUNCTION OF NICR IN VIVO
In the study by Kakizawa et al. (41), NICR was induced by phys-
iological patterns of neuronal activity (BS to PF) in artificial
cerebrospinal fluid (ACSF) bubbled with 95% O2/5% CO2. In the
component of PF-PC synapse, expression of nNOS is observed
in PFs and NO is thought to be released from PF terminal (60,
61). Thus, NO, produced at PF in response to the neuronal activ-
ity, is thought to diffuse and induce S-nitrosylation of RyR1 in
PCs. As is already demonstrated by Eu et al. (35), RyR1 is S-
nitrosylated in the ambient pO2 levels only when the concentration
of NO is micromolar level (35). Is the level of NO produced by
the BS inducing NICR and PF-LTP micromolar range? Using the
NO-sensitive fluorescent probe, Namiki et al. (54) estimated the
BS-induced NO level in PCs in the cerebellar slice (54). The NO
concentration induced by the BS was estimated to the order of
∼5µM. Correspondingly, in the cerebellar PCs,NICR was induced
when NOC7 was higher than 10µM (Kakizawa et al., unpublished
data), and 10µM NOC7 is estimated to yield ∼1µM NO (54).
Thus, NICR is suggested to be induced by physiological patterns
of neuronal activity, which induces PF-LTP, through the micro-
molar levels of NO in the ambient pO2 condition. On the other
hand, it is still possible that the level of NO required for the
induction of NICR and PF-LTP is overestimated. because pO2
at tissue level (∼10 mmHg) is much lower than the ambient level
(∼150 mmHg), and the submicromolar levels of NO is indicated
to induce S-nitrosylation and activation of RyR1 at the tissue pO2
levels (35).
Expressions of RyR1 as well as NOS (especially nNOS) are
observed in various regions of the brain (43, 60). Furthermore,
expression of RyR1 is demonstrated in various tissues other than
brain and skeletal muscles, such as digestive tissues and repro-
ductive tissues (42). Therefore, NICR may have a wide range of
physiological functions in these tissues.
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